(IN BRIEF) Researchers at the Technical University of Munich (TUM) have developed an inhalable RNA-based drug that targets macrophages, overactive…
Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating…
New work by LMU researchers demonstrates that macrophages can effectively substitute for so-called dendritic cells as primers of T-cell-dependent immune…